Home -> Law Blog Directory -> Personal Injury Law Blogs -> New York City Personal Injury Lawyer
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Personal Injury Law
: New York City Personal Injury LawyerMylan's Generic Version of Prilosec Approved by FDA
By Chrissie Cole
A generic formulation of Prilosec, from Mylan, has been approved by the U.S. Food and Drug Administration (FDA) for immediate launch.
Prilosec, marketed by AstraZeneca, is used for the treatment of gastric ulcers and gastro-esophageal reflux disease.
Acid reflux or "heartburn" occurs when acid escapes from the stomach and moves up and into the esophagus. The esophagus is not designed to withstand stomach acid.
The new approval is for 40-mg delayed-release capsules. Previously approved versions of Impax's generic Prilosec, including 10 and 20-mg capsules are one of 12 products included in an alliance which first launched in 2001 with a subsidiary of Teva Pharmaceuticals Industries Ltd.
Originally posted at InjuryBoard by Chrissie Cole
Full post as published by New York City Personal Injury Lawyer on January 23, 2009 (boomark / email).
ETHEX Corp
5 Generic Drugs Recalled Due to Risk of Death From Overdose
Generic Versions
Barr Pharmaceuticals to pay $5.9 million settlement for blocking the sale of oral contraceptives.
Hartford Class Action Settlement of $72.5M Approved
$72.5M Hartford Settlement Approved
$5.4 Million Quebec Breast Cancer Wait List Class Action Settlement Approved
$5.4 Million Quebec Breast Cancer Class Action Settlement Approved
Preliminary Audi Volkswagen Settlement Approved
Preliminary Audi Volkswagen Settlement Approved
$47.5 Million Settlement Approved for September 11 Plaintiffs
$47.5 Million Settlement Approved for September 11 Plaintiffs

Mylan Prevails Over AstraZeneca in Appeal of Prilosec Case
Novartis Sues Mylan Over Generic Version of Lescol
AstraZeneca Suffers Reflux Over Generic Omeprazole
Wyeth undercuts Teva on Protonix
Nexium/Prilosec Antitrust Decision
Mylan and Novartis Settle Femara® Litigation









